Info@ThinkPinkRocks.org

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43{20b543310651bf6f3679f07daa0e532ca50e05ab066d8bcfc12d35f979f65272} compared to placebo.

Continue reading here:
Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes